Recent Blog Articles


Promising results for a targeted drug in advanced prostate cancer

February 11, 2016
  • By Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases

About the Author

photo of Charlie Schmidt

Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases

Charlie Schmidt is an award-winning freelance science writer based in Portland, Maine. In addition to writing for Harvard Health Publishing, Charlie has written for Science magazine, the Journal of the National Cancer Institute, Environmental Health Perspectives, … See Full Bio
View all posts by Charlie Schmidt


As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.

No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.


February 29, 2016

thanks from your site and Beneficial Articles.
pls connect me to a letter about cancer treatment with
nano gold particles.

with respect

February 12, 2016

is this testing available now to anyone?

Dr. Thomas Pane
February 11, 2016

Hi Charles, thanks for getting this blog out. Interesting conclusion of the study.. “Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.” This is a field that we will be paying more attention to later.

Commenting has been closed for this post.

Free Healthbeat Signup

Get the latest in health news delivered to your inbox!